Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as $15.24 and last traded at $14.23, with a volume of 3,493,447 shares changing hands. The stock had previously closed at $11.75.

Several equities analysts have recently commented on the stock. Piper Jaffray Cos. set a $16.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 18th. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $14.00 target price for the company in a research report on Tuesday, August 2nd. Brean Capital set a $20.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, July 28th. Finally, Jefferies Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Friday, June 10th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $16.83.

The company’s market capitalization is $600.78 million. The stock has a 50-day moving average price of $11.83 and a 200-day moving average price of $9.77.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.12. The company had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $36.03 million. The business’s quarterly revenue was up 30.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.13) EPS. On average, equities analysts anticipate that Vanda Pharmaceuticals Inc. will post ($0.61) earnings per share for the current year.

A hedge fund recently raised its stake in Vanda Pharmaceuticals stock. Bank of Montreal Can increased its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 23.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,208,918 shares of the biopharmaceutical company’s stock after buying an additional 228,074 shares during the period. Bank of Montreal Can owned 2.82% of Vanda Pharmaceuticals worth $11,255,000 at the end of the most recent reporting period.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.